ReviewThe Ulster medical journal2017
Cardiotoxicity Following Cancer Treatment.
Review in The Ulster medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].Der Urologe. Ausg. A · 2019Pooled it
- Cardiac Cancer: An Evidence-Based Study of Occurrence.Current cardiology reviews · 2026Article
- Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Chemotherapy periodization to maximize resistance training adaptations in oncology.Cancer chemotherapy and pharmacology · 2023Article
- Validation of an established deep learning auto-segmentation tool for cardiac substructures in 4D radiotherapy planning scans.Physics and imaging in radiation oncology · 2022Article
- Increased standardised incidence ratio of cardiovascular diseases among colorectal cancer patients.International journal of colorectal disease · 2022Article
- Clinical implications of chemotherapeutic agent organ toxicity on perioperative care.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Florida Inter-Specialty Collaborative Project to Improve Cardio-Oncology Awareness and Identify Existing Knowledge Gaps.JACC. CardioOncology · 2020Article
- Cardiotoxicity of Anticancer Therapeutics.Frontiers in cardiovascular medicine · 2018Review
- Synergistic apoptotic effects of apigenin TPGS liposomes and tyroservatide: implications for effective treatment of lung cancer.International journal of nanomedicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
More than half of those born after 1960 will develop cancer during their lifetime. Fortunately, owing to improved diagnosis and treatment, cure rates have risen steadily over the last three decades. With an increased survivorship, more will experience adverse effects of cancer therapeutics on the heart. As the oncologist's focus begins to encompass the issues of cancer survivorship, awareness of the management of cardiac toxicity would be prudent for all physicians looking after patients with cancer.
Indexed as
Identifiers
28298705PMC5324172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.